• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Mandatory Blood Screening to Prevent Transfusion-Transmission of Zika Virus

August 29, 2016

Zika virus in Brazil, illustration

Two platelet transfusion recipients acquired the Zika virus from their transfusions, as recently reported in The New England Journal of Medicine.  Both patients were transfused with leukoreduced platelets from one presymptomatic Zika-infected donor. Both recipients were negative for the virus pre-transfusion, but samples collected from both recipients after transfusion were positive for Zika virus.  Furthermore, sequencing data confirmed that Zika virus isolates were related between the donor and both patients.  Since transfusion-transmission of the Zika virus has been confirmed in Brazil, along with numerous mosquito-borne and travel-related cases of Zika in the United States, the U.S. Food and Drug Administration (FDA) has revised their guidance recommendations. The FDA now recommends universal testing of all donated blood products using an investigational individual donor nucleic acid test (ID-NAT) for Zika virus.  Universal ID-NAT testing for Zika virus shall be implemented nationwide in phases over the next 12 weeks.  As an alternative option to ID-NAT testing, the FDA also endorses using an FDA-approved pathogen reduction technology for plasma and platelets.  Under these recommendations, donors will not need to be deferred due to Zika virus risk factors.  The transfusion medicine community should continue to monitor updates from the Centers for Disease and Control, FDA and other government officials.

References:

  1. Motta IJ, Spencer BR, Cordeiro da Silva SG, Arruda MB, Dobbin JA, Gonzaga YB, Arcuri IP, Tavares RC, Atta EH, Fernandes RF, Costa DA, Ribeiro LJ, Limonte F, Higa LM, Voloch CM, Brindeiro RM, Tanuri A, Ferreira OC, Jr. Evidence for Transmission of Zika Virus by Platelet Transfusion. N Engl J Med 2016.
  2. CDC website. Zika Virus Disease in the United States, 2015-2016. July 27, 2016. Accessed online August 21, 2016.  http://www.cdc.gov/zika/geo/united-states.html 
  3. U.S. Department of Health and Human Services Food and Drug Administration.   Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components. Accessed online August 28, 2016. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM518213.pdf

 

Filed Under

  • Blood Donation
  • News
  • Quality Control and Regulatory
  • Transfusion Transmitted Infections

Recommended

  • Transfusion Patients with Hereditary Hemorrhagic Telangiectasia Have Increased Risk of Alloimmunization

  • L-leucine May Play Therapeutic Role in Diamond-Blackfan Anemia

  • Behavior Modifications Support Changes to Restrictive RBC Transfusion Practices

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Directed Blood Donations Should be Limited

  • Babesia Infection Reduces Red Cell Deformability

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley